INTERNATIONAL SEARCH REPORT

Inter mal Application No PCT/EP 99/06298

	-		101/11 33/	00230
a. classi IPC 7	FICATION OF SUBJECT MATTER A61K31/70			
According to	o International Patent Classification (IPC) or to both national classific	ation and IPC		
B. FIELDS	SEARCHED			
Minimum do IPC 7	ocumentation searched (classification system followed by classification $A61K$	on symbols)		
	tion searched other than minimum documentation to the extent that s			
Electronic d	ata base consulted during the international search (name of data ba	se and, where practical	l, search terms used)	
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		···	
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages		Relevant to claim No.
P,X	QUINTIERI, L. ET AL: "Delivery of methoxymorpholinyl doxorubicn by interleukin 2-activated NK cells: Effect in mice bearing hepatic metastases" BRITISH JOURNAL OF CANCER, vol. 79, no. 7-8, March 1999 (1999-03), pages 1067-1073, XP000893191 the whole document		1,4,5,8, 13,15, 16,18,19	
X	VASEY, P.A. ET AL: "Phase I clinical and pharmacokinetic study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)dox orubicin (FCE 23762)" CANCER RESEARCH, vol. 55, no. 10, 1995, pages 2090-2096, XP000891501 the whole document especially page 2091, Table 1		1-3,5, 10-12, 18,19	
X Furth	ner documents are listed in the continuation of box C.	Patent family	members are listed in	n annex.
° Special cat	tegories of cited documents :	"T" later document sub	lighed after the list-	national filing date
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "X" document of particular relevance; the claimed invention				
"L" document which is citation	nt which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) ant referring to an oral disclosure, use, exhibition or	involve an inventive "Y" document of particue cannot be conside document is comb	ular relevance; the cla gred to involve an involve ined with one or mor	ument is taken alone aimed invention entive step when the e other such docu
"P" docume	nt published prior to the international filing date but	ments, such comb in the art. "&" document member	ination being obvious of the same patent for	·
Date of the a	actual completion of the international search		the international sear	
17	7 April 2000	03/05/2	000	
Name and m	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Authorized officer Mair, J		

1

INTERNATIONAL SEARCH REPORT

Inter mal Application No
PCT/EP 99/06298

		7EP 99/06298			
	C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.				
Category	Citation of occurrent, with indication, where appropriate, or the relevant passages	Helevant to claim No.			
X	TAUB, R.N. ET AL: "Phase II study of methoxymorpholinodoxorubicin in advanced sarcomas (PNU/S2243 (FCE 23762))" PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 16, 1997, page A1831 XP002135896 abstract	1,4-6, 18,19			
X	BAKKER, M. ET AL: "Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients" BRITISH JOURNAL OF CANCER, vol. 77, no. 1, January 1998 (1998-01), pages 139-146, XP000893190 the whole document especially page 140, Table 1	1,4-6, 18,19			
Y	ROBERT, J. ET AL: "Pharmacokinetics and metabolism of anthracyclines" CANCER SURVEYS, vol. 17, 1993, pages 219-252, XP000893095 page 228, line 4 -page 229, line 38 page 239, line 25 -page 242, line 23 especially page 242, line 15-17	1-5,8,9, 13-19			
Y	ROUGIER, P. ET AL: "Intérêt des chimiothérapies loco-régionales par les anthracyclines" PATHOLOGIE BIOLOGIE, vol. 35, no. 1, 1987, pages 123-128, XP000893118 the whole document especially page128, righthand column	1-5,8,9, 13-19			
Y	KIRK, S. ET AL: "Irresectable hepatoma treated by intrahepatic iodized oil doxorubicin hydrochloride: Initial results" SURGERY, vol. 109, no. 6, 1991, pages 694-697, XP000893192 the whole document	1-5,8,9, 13-19			
Y	CARR, B.I. ET AL: "Prolonged survival with chemotherapy alone for hepatocellular carcinoma (HCC) with intra-arterial chemotherapy" PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, vol. 13, March 1994 (1994-03), page 205 XP000893111 abstract	1-5,8,9, 13-19			

1

INTERNATIONAL SEARCH REPORT

Interr nal Application No PCT/EP 99/06298

Category Citation of document, with indication, where appropriate, of the relevant passages Y CARR, B.I. ET AL: "Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin in the treatment of advanced—stage	Relevant to claim No.
Y CARR, B.I. ET AL: "Phase II study of Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin	
Spherex (degradable starch microspheres) injected into the hepatic artery in conjunction with doxorubicin and cisplatin	1-5,8,
hepaccellular carcinoma: Interim analysis" SEMINARS IN ONCOLGY, vol. 24, no. 2 suppl. 6, April 1997 (1997-04), pages S6-97-S6-99, XP000893102 the whole document	13,15, 16,18,19

1